FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.
What happened
In June 2025, FDA reviewed the website drjennpb.com and observed that it offered compounded drug products including retatrutide and semaglutide. FDA said the compounded retatrutide products are unapproved new drugs and misbranded, and that the website’s semaglutide claims are false or misleading.
What FDA found
The compounded retatrutide products are unapproved new drugs because FDA has no approved application for them.
FDCA §§ 505(a), 301(d) [21 U.S.C. §§ 355(a), 331(d)]The retatrutide labeling lacks adequate directions for use, so the products are misbranded.
FDCA §§ 502(f)(1), 301(a) [21 U.S.C. §§ 352(f)(1), 331(a)]The retatrutide products do not qualify for the special exemptions for certain compounded drugs because retatrutide is not on the relevant bulk drug lists, is not an FDA-approved drug component, and is not on the shortage list.
FDCA §§ 503A(b)(1)(A)(i), 503B(a)(2)(A)(i) [21 U.S.C. §§ 353a(b)(1)(A)(i), 353b(a)(2)(A)(i)]The semaglutide claim “FDA Approved” is false or misleading because compounded drugs are not FDA-approved.
FDCA §§ 502(a), 502(bb), 301(a) [21 U.S.C. §§ 352(a), 352(bb), 331(a)]The claims “USA Compounded,” “Custom Compounded,” and “Generic Ozempic” imply the semaglutide is the same as an FDA-approved product when it is not.
FDCA §§ 502(a), 502(bb), 301(a) [21 U.S.C. §§ 352(a), 352(bb), 331(a)]
What FDA wants
FDA tells the company to take immediate action to stop the violations, including ceasing the misleading language, and to send a written response within 15 working days describing steps taken and how recurrence will be prevented, with documentation.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and physicians that use retatrutide or semaglutide
- marketing teams making FDA-approval or generic-drug claims
This is a summary. Read the original letter on fda.gov.